Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

313 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study.
Macaluso FS, D'Antonio E, Fries W, Viola A, Ksissa O, Cappello M, Muscarella S, Belluardo N, Giangreco E, Mocciaro F, Di Mitri R, Ferracane C, Vitello A, Grova M, Renna S, Casà A, De Vivo S, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: cappello m. Dig Liver Dis. 2024 Jan;56(1):15-20. doi: 10.1016/j.dld.2023.08.061. Epub 2023 Sep 22. Dig Liver Dis. 2024. PMID: 37741749
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
Macaluso FS, Grova M, Mocciaro F, Di Mitri R, Privitera AC, Distefano ME, Vitello A, Camilleri S, Ferracane C, Pluchino D, Belluardo N, Giangreco E, Fries W, Viola A, Cappello M, D'Amato L, Bertolami C, Ventimiglia M, Renna S, Casà A, D'Antonio E, De Vivo S, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: cappello m. J Gastroenterol Hepatol. 2023 Sep;38(9):1503-1509. doi: 10.1111/jgh.16208. Epub 2023 May 6. J Gastroenterol Hepatol. 2023. PMID: 37148148
Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study.
Ribaldone DG, Parisio L, Variola A, Bossa F, Castiglione F, Marzo M, Piazza N, Aratari A, Savarino EV, Bodini G, Mastronardi M, Micheli F, Mazzuoli S, Ascolani M, Viganò C, Cappello M, Bezzio C, Ciccocioppo R, Scardino G, Sarli E, Pugliese D, Scaldaferri F, Napolitano D, Todeschini A, Geccherle A, Colaci N, Guerra M, Annese M, Testa A, Caiazzo A, Conforti FS, Festa S, Lorenzon G, Marra A, Magiotta A, Baccini F, Amato A, Poshnjari A, Vernero M, Caprioli F, Caviglia GP; Italian Group for the study of Inflammatory Bowel Disease (IG-IBD). Ribaldone DG, et al. Among authors: cappello m. Dig Liver Dis. 2024 Jan;56(1):77-82. doi: 10.1016/j.dld.2023.07.011. Epub 2023 Jul 19. Dig Liver Dis. 2024. PMID: 37474412
Golimumab improves health-related quality of life of patients with moderate-to-severe ulcerative colitis: Results of the go-care study.
Saibeni S, Bezzio C, Bossa F, Privitera AC, Marchi S, Roselli J, Mazzuoli S, Geccherle A, Soriano A, Principi MB, Viola A, Sarpi L, Cappello M, D'Incà R, Mastronardi M, Bodini G, Guerra M, Benedetti A, Romano M, Cicala M, Di Sabatino A, Scaldaferri F, De Rosa T, Giardino AM, Germano V, Orlando A, Armuzzi A. Saibeni S, et al. Among authors: cappello m. Dig Liver Dis. 2024 Jan;56(1):83-91. doi: 10.1016/j.dld.2023.07.031. Epub 2023 Aug 12. Dig Liver Dis. 2024. PMID: 37574431 Free article.
Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease.
Bezzio C, Franchellucci G, Savarino EV, Mastronardi M, Caprioli FA, Bodini G, Variola A, Scaldaferri F, Furfaro F, Calabrese E, Principi MB, Biscaglia G, Marzo M, Michielan A, Cavalli C, Aratari A, Campigotto M, Ceccarelli L, Cappello M, Saibeni S, Balestrieri P, Soriano A, Casini V, Bertani L, Barberio B, Conforti FS, Danese S, Armuzzi A. Bezzio C, et al. Among authors: cappello m. Crohns Colitis 360. 2024 Oct 24;6(4):otae060. doi: 10.1093/crocol/otae060. eCollection 2024 Oct. Crohns Colitis 360. 2024. PMID: 39525291 Free PMC article. No abstract available.
The Effectiveness of Risankizumab as Induction Therapy for Crohn's Disease: Data From the Sicilian Network for Inflammatory Bowel Diseases.
Macaluso FS, Renna S, Fries W, Viola A, Cappello M, Salerno IA, Mocciaro F, Scrivo B, Giangreco E, Ferracane C, Minissale MG, Distefano ME, Tortorella V, Termini A, Bertoncello L, Orlando A. Macaluso FS, et al. Among authors: cappello m. Inflamm Bowel Dis. 2024 Oct 26:izae248. doi: 10.1093/ibd/izae248. Online ahead of print. Inflamm Bowel Dis. 2024. PMID: 39460746
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium.
Lenti MV, Ribaldone DG, Borrelli de Andreis F, Vernero M, Barberio B, De Ruvo M, Savarino EV, Kav T, Blesl A, Franzoi M, Gröchenig HP, Pugliese D, Ianiro G, Porcari S, Cammarota G, Gasbarrini A, Spagnuolo R, Ellul P, Foteinogiannopoulou K, Koutroubakis I, Argyriou K, Cappello M, Jauregui-Amezaga A, Demarzo MG, Silvestris N, Armuzzi A, Sottotetti F, Bertani L, Festa S, Eder P, Pedrazzoli P, Lasagna A, Vanoli A, Gambini G, Santacroce G, Rossi CM, Delliponti M, Klersy C, Corazza GR, Di Sabatino A; European Consortium for the study of immune checkpoint inhibitor-induced colitis. Lenti MV, et al. Among authors: cappello m. ESMO Open. 2024 Jul;9(7):103632. doi: 10.1016/j.esmoop.2024.103632. Epub 2024 Jul 5. ESMO Open. 2024. PMID: 38970840 Free PMC article.
Effect of radiation therapy on lymph node fluorescence in head and neck squamous cell carcinoma after intravenous injection of indocyanine green: a prospective evaluation.
Digonnet A, Vankerkhove S, Moreau M, Dekeyser C, Quiriny M, Willemse E, de Saint Aubain N, Cappello M, Donckier V, Bourgeois P. Digonnet A, et al. Among authors: cappello m. EJNMMI Res. 2024 May 16;14(1):47. doi: 10.1186/s13550-024-01106-5. EJNMMI Res. 2024. PMID: 38753288 Free PMC article.
313 results